20-F: OKYO Pharma Reports Mixed Financials Amid Strategic Shift to Neuropathic Corneal Pain and Fast Track Designation

OKYO Pharma Limited reported a reduced net loss for the fiscal year ended March 31, 2025, driven by lower R&D and administrative expenses, while strategically accelerating its lead drug candidate urcosimod for neuropathic corneal pain after receiving Fast Track designation.

Summary

• Net loss for the fiscal year ended March 31, 2025, significantly decreased to $4.7 million, compared to $16.8 million in the prior year.
• Research and development expenses decreased by $5.99 million to $2.25 million for the year ended March 31, 2025, primarily due to the completion of the larger DED clinical trial and the initiation of a smaller, less costly NCP trial.
• General and administrative expenses decreased by $2.67 million to $4.84 million, mainly due to reductions in chairman and employee bonuses, D&O insurance premiums, and consultancy spend.
• An income tax credit of $3.26 million was recognized for the year ended March 31, 2025, attributed to tax receipts for 2023 R&D expenditure credits ($1.41 million) and a provision for expected 2024 R&D credits ($1.85 million).
• Cash and cash equivalents stood at $1.56 million as of March 31, 2025, with a working capital deficit of $5.55 million.
• The company's independent registered public accounting firm, PKF Littlejohn, LLP, expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing by July 2026.
• OKYO Pharma's lead drug candidate, urcosimod (formerly OK-101), received Fast Track designation from the FDA for the treatment of neuropathic corneal pain (NCP) on May 1, 2025.
• The Phase 2 clinical trial for urcosimod in NCP was strategically closed early after 17 patients completed the study, with data analysis expected within 6 weeks from April 30, 2025, to accelerate the path to an end-of-phase 2 meeting with the FDA.
• Initial results from the 18-patient Phase 2 NCP trial showed that the 0.05% urcosimod group had a mean pain score reduction of 5.5 compared to 2.75 in the placebo group in the per-protocol population, with 75% of patients achieving greater than 80% improvement in pain severity.
• The 0.05% urcosimod group demonstrated a statistically significant reduction in mean pain scores from baseline to end of treatment (p-value = 0.025) in the per-protocol population, despite the overall between-group difference not reaching statistical significance (p=0.07) due to the small sample size.
• The 0.1% urcosimod dose showed less efficacy than the 0.05% dose, an observation consistent across two independent trials.
• Urcosimod was officially assigned the United States Adopted Name (USAN) urcosimod on February 12, 2025, denoting its classification as a modulator of inflammatory and neuropathic pathways.
• The company successfully established that urcosimod is stable for over two and a half years in single-use ampoules, which are increasingly preferred for ophthalmic drug administration.
• In mid-2024, the company shifted its primary clinical development focus for urcosimod from Dry Eye Disease (DED) to NCP, citing positive ocular pain reduction data in the DED trial and the lack of FDA-approved topical drugs for NCP.
• Previous Phase 2b DED trial results (January 8, 2024, and March 22, 2024) showed urcosimod achieved statistical significance in various sign and symptom endpoints, including burning, blurred vision, total conjunctival staining, ocular pain, and tear film break-up time, with a placebo-like tolerability profile.
• The company has 8 issued patents and 15 pending patent applications as of June 30, 2025, covering urcosimod and OK-201, with expected expiration dates between 2034 and 2043, excluding extensions.
• Post March 31, 2025, the company raised an additional $2.7 million through its ATM facility.
• The company entered into unsecured loan agreements with an existing shareholder totaling $950,000 between September 2024 and January 2025, convertible into shares at $0.70 per share with a 20% annual interest rate.
• The company continues to rely on third parties for preclinical studies, clinical trials, and manufacturing, which introduces risks related to management control, compliance, and supply chain disruptions.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are significant positives like Fast Track designation, promising early clinical data for NCP, and reduced operating losses, the persistent going concern warning, substantial accumulated deficit, and ongoing need for significant capital raise temper optimism. The strategic early trial closure for NCP is a calculated risk that could accelerate development but also means less robust data for initial statistical significance.

Positives

• Net loss significantly reduced to $4.7 million in FY2025 from $16.8 million in FY2024, indicating improved financial efficiency.
• Research and development expenses decreased substantially by $5.99 million, reflecting a strategic shift to a smaller, less costly clinical trial for NCP.
• General and administrative expenses decreased by $2.67 million, demonstrating cost control measures.
• Received an income tax credit of $3.26 million in FY2025, primarily from R&D expenditure credits.
• Urcosimod received Fast Track designation from the FDA for neuropathic corneal pain (NCP), which can accelerate development and review.
• Initial Phase 2 NCP trial results for the 0.05% urcosimod dose showed a strong treatment effect (Cohen-d > 1.2) and a statistically significant reduction in pain scores (p=0.025) in the per-protocol population, with 75% of patients achieving over 80% pain improvement.
• The strategic early closure of the Phase 2 NCP trial aims to accelerate data analysis and an end-of-phase 2 meeting with the FDA, potentially speeding up further clinical development.
• Urcosimod demonstrated stability for over two and a half years in single-use ampoules, which is beneficial for commercialization and patient convenience.
• Previous Phase 2b DED trial showed urcosimod achieved statistical significance in multiple FDA-recognized efficacy endpoints (signs and symptoms) and exhibited placebo-like tolerability.
• The company has a robust intellectual property portfolio with 8 issued patents and 15 pending applications, providing protection for its product candidates.
• Successfully raised an additional $2.7 million post-fiscal year end through its ATM facility, demonstrating continued access to capital.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $143 million as of March 31, 2025.
• A working capital deficit of $5.55 million as of March 31, 2025, indicates short-term liquidity challenges.
• The independent registered public accounting firm expressed substantial doubt about the company's ability to continue as a going concern without additional financing by July 2026.
• The Phase 2 NCP trial, while showing promising numerical results, did not achieve statistical significance in the between-group difference (p=0.07) for the per-protocol population, and the intent-to-treat population also lacked statistical significance (p=0.2), due to the small sample size from early termination.
• The 0.1% urcosimod dose consistently showed less efficacy than the 0.05% dose in both DED and NCP trials, requiring further explanation and potentially limiting dosage flexibility.
• The company has not generated any revenue from product sales to date and does not expect to in the near future, relying heavily on external financing.
• The company is dependent on third parties for clinical trials and manufacturing, which introduces risks related to control, compliance, and potential disruptions.
• The company's FPI status allows it to follow Guernsey corporate governance rules, which differ from NASDAQ standards, potentially offering less protection or information to U.S. investors.

Risks

• Product candidates are in early stages of development, and revenue generation is not expected for several years, if ever, with a high degree of failure for product candidates in clinical trials.
• Clinical trial data may be interpreted in varying ways, potentially delaying, limiting, or preventing future regulatory approvals.
• There is a substantial risk of adverse, undesirable, unintended, or inconclusive results from testing or pre-clinical/clinical trials, which may delay or halt development.
• The company will need to raise substantial additional capital to develop and commercialize product candidates, and failure to obtain funding may force delays, reductions, or elimination of development programs.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern, which may hinder future financing.
• Significant losses are anticipated for the foreseeable future, dependent on the rate of future expenditures and success in commercializing products.
• Even if regulatory approval is received, commercialization may be inhibited by inability to recruit sales personnel, unforeseen marketing costs, or failure to secure suitable pricing/reimbursement.
• Competition from major multinational pharmaceutical companies, universities, and research institutions with greater resources poses a significant challenge.
• Dependence on third-party supply, development, manufacturing, and clinical service relationships creates risks regarding management control, compliance, and timely delivery.
• Insurance coverage and reimbursement for products may be limited, unavailable, or reduced over time, impacting profitability.
• Expiration or inability to obtain, maintain, or enforce adequate intellectual property rights may result in additional competition or require compensation to third parties.
• Third parties may have blocking intellectual property rights, preventing sales or requiring compensation.
• Inability to prevent disclosure of trade secrets, know-how, or other proprietary information could diminish technology value.
• Product candidates could infringe patents and other intellectual property rights of third parties, leading to costly litigation or licensing requirements.
• Growth may place significant demands on management and resources, and challenges in identifying and retaining key personnel could impair operations.
• Inherent risk of product liability claims and associated adverse publicity from clinical testing and future product sales.
• Employees, contractors, consultants, and commercial partners may engage in misconduct or improper activities, including non-compliance with regulatory standards.
• Vulnerability to disruptions of information technology systems or breaches of data security could compromise sensitive information and expose the company to liability.
• The relationship of the UK with the EU (Brexit) could impact the ability to operate efficiently in certain jurisdictions or markets, potentially delaying regulatory approvals.
• Uncertainty regarding when or if regulatory approval will be obtained, and whether approval may be for a narrower indication than sought.
• Delays in obtaining regulatory approval of manufacturing processes and facilities or disruptions in manufacturing may delay product development and commercialization.
• If competitors obtain orphan drug exclusivity for similar products, the company may be precluded from approval for a significant period.
• Even if regulatory approval is obtained, product candidates will remain subject to ongoing regulatory oversight and requirements.
• Healthcare legislative reform measures in the U.S. and other jurisdictions may negatively impact business and results of operations by limiting coverage or reducing reimbursements.
• Stringent and changing privacy laws, regulations, and standards (e.g., GDPR, CCPA) and contractual obligations related to data privacy and security could harm reputation or subject the company to fines.
• Subject to anti-corruption laws (e.g., U.K. Bribery Act, FCPA) and trade control laws, with potential for criminal and civil penalties for non-compliance.
• Relationships with customers, physicians, and third-party payors will be subject to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or substantial costs.
• The prices of ordinary shares may be volatile and fluctuate substantially, resulting in losses for shareholders.
• Rights of shareholders may differ from those typically offered to shareholders of a U.S. corporation due to Guernsey incorporation.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute shareholders, or incur debt/contingent liabilities.
• Loss of Foreign Private Issuer (FPI) status would require compliance with more extensive U.S. domestic reporting requirements, increasing costs.
• As an Emerging Growth Company (EGC), the company takes advantage of reduced reporting requirements, which may make its shares less attractive to some investors.
• Failure to establish and maintain proper internal controls could impair the ability to produce accurate financial statements or comply with regulations.
• Claims of U.S. civil liabilities may not be enforceable against the company due to its Guernsey incorporation and non-U.S. resident directors/management.
• The insolvency laws of Guernsey and other jurisdictions may not be as favorable to investors as U.S. bankruptcy laws.
• Classification as a Passive Foreign Investment Company (PFIC) could result in adverse U.S. federal income tax consequences to U.S. holders.
• A change in tax residence could have a negative effect on future profitability.
• Inability to use net operating loss and tax credit carryforwards or benefit from favorable U.K. tax legislation could increase tax payments.
• Changes and uncertainties in the tax system in operating countries could adversely affect financial condition and results.

Future Outlook

The company anticipates continued significant losses for the foreseeable future as it advances preclinical activities, manufacturing, and clinical trials for its product candidates. Future funding requirements are expected to increase substantially, driven by regulatory approvals, establishment of commercial infrastructure, increased headcount, and intellectual property maintenance. The company expects to finance its cash needs through equity offerings and other financing activities such as debt arrangements until it can generate sufficient product revenue to achieve profitability. The company plans to request an end-of-phase 2 meeting with the FDA to discuss further clinical development plans for urcosimod in NCP following the early closure and analysis of the Phase 2 trial data.

Management Comments

• "We were pleased to announce on February 12, 2025, that our lead drug candidate, OK-101, was officially assigned the United States Adopted Name (USAN) urcosimod."
• "Based on the success of the animal model experiments, we concluded that urcosimod has the potential to address both the increased inflammatory cytokines resulting from tear film imbalance as well as heightened neurosensory abnormalities through peripheral corneal nerve damage."
• "Consequently, we believe that urcosimod has the potential to treat neuropathic corneal pain."
• "The decision to close the trial with 17 patients having presently completed the study was due to our strong desire to immediately interrogate the currently masked data by unmasking the data set."
• "This decision to close the trial would also enable us to significantly cut the time to our requesting an end-of-phase 2 meeting with FDA to cover plans for the drugs further clinical development."
• "The Company has an active effort underway to provide an explanation for this difference in efficacy [between 0.05% and 0.1% doses]."
• "OKYO is also continuing to evaluate additional data from this trial and plans to present a larger data set from the study after ongoing analyses of the data have been completed."
• "The Directors are taking steps to put engagements and plans into place to ensure that sufficient funds will be forthcoming to progress the clinical pipeline."
• "These steps include deferred payments of existing liabilities, working capital cost reductions and raising additional equity."
• "The Directors are confident, based on the previous fund-raising history as well as additional measures being planned, that sufficient funds will be forthcoming and accordingly they have prepared these financial statements on a going concern basis."

Industry Context

OKYO Pharma operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on inflammatory eye diseases and ocular pain. Its lead candidate, urcosimod, targets CMKLR1, a novel G Protein-Coupled Receptor. The strategic shift to Neuropathic Corneal Pain (NCP) is notable because, unlike Dry Eye Disease (DED) which has seven FDA-approved treatments, NCP currently has no FDA-approved topical drugs, representing a significant unmet medical need. The Fast Track designation for urcosimod in NCP aligns with industry efforts to accelerate therapies for serious conditions with unmet needs. The company's reliance on third-party CROs and CMOs is a common strategy for smaller biopharmaceutical companies to manage R&D and manufacturing costs.

Comparison to Industry Standards

• The company's financial position, characterized by recurring losses and a going concern warning, is not uncommon for pre-revenue, clinical-stage biopharmaceutical companies, which typically require substantial capital investment over long development cycles before commercialization.
• The strategic decision to pivot from DED to NCP, despite positive DED trial data, is a common industry practice for companies seeking to address higher unmet medical needs and potentially achieve faster regulatory pathways (e.g., Fast Track designation) where competition is less intense.
• The Fast Track designation for urcosimod in NCP is a positive indicator, aligning with FDA's programs to expedite development of drugs for serious conditions, similar to how other companies like Regeneron Pharmaceuticals (for Eylea in retinal diseases) or Alcon (for various ophthalmic solutions) navigate regulatory pathways, though OKYO is at a much earlier stage.
• The observed difference in efficacy between the 0.05% and 0.1% doses of urcosimod, consistent across two trials, highlights a common challenge in drug development where optimal dosing can be complex and non-linear, requiring further mechanistic understanding, similar to dose-response studies seen with companies developing therapies for chronic conditions.
• The company's intellectual property strategy, including patenting composition of matter and methods of use, is standard for biopharmaceutical firms aiming to protect their innovations and secure market exclusivity, comparable to the patent portfolios of larger ophthalmic drug developers like Novartis (with Xiidra) or AbbVie (with Restasis).

Corporate Governance

Related Party Transactions

• The company has a Shared Services agreement with Tiziana Life Sciences Ltd (controlled by Gabriele Cerrone, Non-Executive Chairman). In FY2025, the company incurred $142,170 in costs under this agreement, with $431,305 due to Tiziana as of March 31, 2025. Tiziana also paid $350,802 in costs on behalf of the company, with $428,020 due to Tiziana as of March 31, 2025.
• A $2 million short-term credit facility from Tiziana Life Sciences Ltd (August 2022) and an additional $0.5 million facility (February 2023) were converted into 2,100,000 Ordinary Shares on October 25, 2023, including $1.15 million in accrued interest.
• On July 15, 2024, 500,000 Ordinary Shares were issued to Tiziana Life Sciences Ltd in lieu of an additional $750,000 in accrued interest related to the previous loan agreement.
• The company entered into three fixed-term unsecured loan agreements with an existing shareholder (not explicitly named as a director or executive, but 'existing shareholder' implies related party) totaling $950,000 between September 2024 and January 2025. These loans carry a 20% annual interest rate and are convertible into shares at $0.70 per share.
• As of March 31, 2025, the company owed fees to its directors: John Brancaccio ($53,760), Bernard Denoyer ($53,760), Gary Jacobs ($43,750), Willy Simon ($57,189), and Gabriele Cerrone ($193,441).

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity raises and convertible loan note conversions. The going concern warning indicates a risk to investment value. However, positive clinical data and Fast Track designation for urcosimod could lead to future value creation if development is successful.
• **Employees**: The company's growth and expansion plans suggest potential for increased headcount, but the financial uncertainty and need for capital raise could impact job security if funding is not secured.
• **Customers (Future Patients)**: The development of urcosimod for NCP addresses a significant unmet medical need, potentially offering a new treatment option for patients suffering from this debilitating condition.
• **Suppliers/Creditors**: The company's working capital deficit and reliance on additional financing pose a risk to timely payment, although the company is taking steps to manage liabilities and raise funds. Related party creditors have converted debt to equity or received shares in lieu of interest, indicating a willingness to support the company's long-term prospects.
• **Regulatory Authorities**: The company's compliance with FDA and other regulatory requirements is critical for product development and commercialization, with non-compliance posing risks of sanctions and delays.

Next Steps

• Analyze the unmasked data from the early-closed Phase 2 NCP trial within 6 weeks from April 30, 2025.
• Request an end-of-phase 2 meeting with the FDA to discuss plans for further clinical development of urcosimod for NCP.
• Seek compassionate use arrangements for patients who completed the NCP trial, subject to FDA consents.
• Continue efforts to provide an explanation for the observed difference in efficacy between the 0.05% and 0.1% doses of urcosimod.
• Evaluate additional data from the Phase 2 NCP trial and present a larger data set after ongoing analyses are completed.
• Raise additional capital through equity offerings and/or debt arrangements to fund ongoing research, development, and potential commercialization.
• Increase personnel headcount to support continued research activities and development of product candidates.
• Expand infrastructure and facilities to accommodate growing employee base.
• Maintain, expand, and protect the intellectual property portfolio.
• Prepare for regulatory filings for any product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure in anticipation of commercializing approved product candidates.

Key Dates

Recommendation

Keywords

OKYO Pharma, urcosimod, OK-101, neuropathic corneal pain, NCP, dry eye disease, DED, biopharmaceutical, clinical-stage, ophthalmic diseases, ocular pain, CMKLR1, ChemR23, G Protein-Coupled Receptor, Fast Track designation, FDA, clinical trials, Phase 2, IND, USAN, intellectual property, patents, licensing, financial results, net loss, R&D expenses, going concern, capital raise, equity financing, convertible loan notes, corporate governance, SEC filing, 20-F, NASDAQ, Guernsey, biotechnology